MicroRNA-155 promotes tumor growth of human hepatocellular carcinoma by targeting ARID2

Introduction

Hepatocellular carcinoma (HCC) is the dominant pathologic type of primary liver cancer, which is the third leading cause of cancer-related death worldwide (1). Despite recent advances in the diagnosis and treatment of HCC, including hepatectomy and liver transplantation, the prognosis for HCC patients remains poor due to the high recurrence rate and early metastasis (2). However, the detailed mechanism underlying the development and progression of HCC is still not clear (3). Therefore, it is urgent to clarify the molecular mechanisms of HCC and identify novel prognostic biomarkers to provide potential therapeutic targets for the patients with HCC.

Increasing evidence suggests that microRNAs (miRNAs), a class of non-coding RNAs composed of ~22 nucleotides, can act as suitable biomarkers with diagnostic, prognostic, and predictive potential (4). miRNAs may function as oncogenes or tumor suppressors by regulating protein expression by interacting with complementary sites within the 3′-untranslated region (UTR) of target mRNA transcripts (5). Emerging studies have documented that aberrant miRNAs play important roles in various biological processes (6), including cell proliferation, differentiation, apoptosis, drug-resistance, migration and invasion (7–10). Recently, miRNAs have shown high stability in tissues and body fluids, which reveal their potential as tumor markers. In addition, it has been widely recognized that dysregulation of miRNAs contribute to the development and progression of HCC.

miR-155 is located within a region known as B cell integration cluster on chromosome 21, which plays a critical role in the progression of gastric cancer (11), colorectal carcinoma (12), lung cancer (13), breast cancer (14), bladder cancer (15) and B-cell lymphoma (16). Previous studies show that miR-155 functions as a regulator in the pathogenesis of cell proliferation, apoptosis, drug-resistance, migration, invasion and epithelial-mesenchymal transition (EMT). miR-155 promotes oral squamous cell carcinoma metastasis and correlates a poor prognosis (17). miR-155 promotes the B-cell lymphoma cell proliferation and inhibits cell apoptosis by targeting NIAM phenocopies (16). Moreover, direct quantitative detection for cell-free miR-155 in urine could be a potential novel biomarker in diagnosis and prognosis for non-muscle invasive bladder cancer (15). miR-155 mediates anti-Warburg effect of rosmarinic acid in colorectal carcinoma and gastric cancer (18). miR-155 presents tamoxifen-resistance by modulating SOCS6-STAT3 signaling pathway in breast cancer (19). However, the clinical significance of miR-155 and the underlying mechanisms involved in the development of HCC remain to be investigated.

In this study, we demonstrated that the expression of miR-155 was upregulated in HCC tissues and its high expression was associated with poor clinicopathological features and the reduced survival of HCC patients. miR-155 promoted cell proliferation, cell cycle and apoptosis resistance in vitro. Moreover, the downregulation of miR-155 inhibited tumor growth of HCC in vivo. Notably, AT-rich interactive domain 2 (ARID2) was identified as a direct target of miR-155. The results showed a new role for miR-155 in prediction of prognosis and promoting tumor growth of HCC.

Materials and methods

Clinical samples and cell lines

HCC samples (124) and matched normal tumor-adjacent samples (>2 cm distance from the margin of the resection) were obtained during surgery and used after obtaining informed consent. All patients underwent resection of their primary HCC in the Department of General Surgery at The Second Affiliated Hospital of Xi'an Jiaotong University, from January 2006 to December 2008. None of the patients received preoperative chemo- or radiotherapy. The stage of cancer was determined according to the cancer staging system published in 2010 by the Union for International Cancer Control (UICC). The Xi'an Jiaotong University Ethics Committee approved all protocols according to the 1975 Helsinki Declaration.

Human HCC cell lines (Hep3B, Bel-7402, MHCC-97L, HepG2, SMMC-7721) and human immortalized normal hepatic cell line LO2 were obtained from the Institute of Biochemistry and Cell Biology, Chinese Academy of Sciences (Shanghai, China). The cells were maintained in Dulbecco's modified Eagle's medium (DMEM, Gibco, Grand Island, NY, USA) containing 10% fetal bovine serum (FBS, Gibco) with 100 U/ml penicillin and 100 μg/ml streptomycin (Sigma, St. Louis, MO, USA) and cultured in a humidified 5% CO2 incubator at 37°C.

Real-time quantitative reverse transcription polymerase chain reaction (qRT-PCR)

Total RNA was extracted from clinical specimens or HCC cells using TRIzol reagent (Invitrogen, Carlsbad, CA, USA) according to the manufacturer's instructions. cDNA was synthesized from 1 μg RNA with the PrimeScript RT Master Mix (Takara, Osaka, Japan). The PCR amplification for the quantification of the miR-155 and U6 was performed using the TaqMan miRNA Reverse Transcription kit (Applied Biosystems, Foster City, CA, USA) and TaqMan Human miRNA Assay kit (Applied Biosystems). The relative expression of miR-155 was shown as the fold difference relative to U6. qPCR primer against mature miRNA miR-155 (HmiRQP0221) and Homo sapiens snRNA U6 qPCR Primer (HmiRQP9001) were purchased from GeneCopoeia (Guangzhou, China).

Western blot analysis

Total protein was extracted from whole cells and 40 μg of isolated protein was separated by 10% SDS-PAGE and transferred onto a PVDF membrane (Bio-Rad Laboratories, Hercules, CA, USA). The membranes were probed with antibodies: anti-Akt, anti-p-Akt, anti-ARID2, anti-Cyclin D, and anti-p27 primary antibodies (Cell Signaling, Danvers, MA, USA) overnight. Then the membranes were incubated with the HRP-conjugated goat anti-mouse or anti-rabbit IgG antibody (ZSGB-BIO, China). Protein bands were visualized using an enhanced chemiluminescence kit (Amersham, Little Chalfont, UK).

Immunohistochemical staining

Immunohistochemistry was performed on paraformaldehyde-fixed paraffin sections. ARID2 (1:100, #13594 Cell Signaling Technology, Inc.) antibody was used in immunohistochemistry by a streptavidin peroxidase-conjugated (SP-IHC) method. The percentage of positive tumor cells was graded as: 0, <10%; 1, 10–30%; 2, 31–50%; 3, >50%.

Plasmids and cell transfection

miRNA vectors, including miR-155 expression vector (HmiR0358-MR02), the control vector for miR-155 (CmiR0001-MR04 and miR-control), miR-155 inhibitor (HmiR-AN0220-AM03 and anti-miR-155) and the negative control for the miR-155 inhibitor (CmiR-AN0001-AM04 and anti-miR-NC), and ARID2 expression plasmid were purchased from GeneCopoeia. The targeted sequences for ARID2 siRNA sense, 5′-AGCTCCAATTCCTTGTGAAGTTTT-3′ and antisense, 5′-ACTTCACAAGGAATTGCAGCTTTT-3′ or a non-specific duplex oligonucleotide as a negative control were produced by Sangon Biotech Co., Ltd. (Shanghai, China). The cells were transfected with the vectors mentioned above using Lipofectamine 2000 according to the manufacturer's instructions (Invitrogen).

Cell cycle, proliferation and detection of apoptosis

Flow cytometry was performed using the fluorescence-activated cell sorting (FACS) Calibur and CellQuest software (both from Becton-Dickinson, San Jose, CA, USA). For cell cycle analysis, the cells were seeded in 6-well plates at 2×105/well. Forty-eight hours after transfection, the cells were fixed in 70% ethanol at 4°C for 24 h and stained with 50 μg/ml propidium iodide (Keygen, Nanjing, China). An Annexin V-Fluor Staining kit (Roche) was used to analyze apoptosis levels. For the proliferation assay, bromodeoxyuridine labeling and immunofluorescence was used. Cells grown on coverslips (Fisher, Pittsburgh, PA, USA) were incubated with bromodeoxyuridine (BrdU) for 1 h and stained with anti-BrdU antibody (Sigma) according to the manufacturer's instructions. Gray level images were acquired under a laser scanning microscope (Axioskop 2 plus, Carl Zeiss Co. Ltd., Jena, Germany).

Luciferase reporter assay

The 3′-UTR sequence of ARID2 predicted to interact with miR-155 or the mutated sequence within the predicted target sites was synthesized and inserted into the pGL3 control vector (Promega, Madison, WI, USA). These constructs were named as wt ARID2-3′UTR or mt ARID2-3′UTR, respectively. Then, SMMC-7721 cells (1×105) were seeded into 24-well plates, and were cultured in OptimMEM reduced serum media (Life Technologies) as per the recommended conditions, and were cotransfected with 200 ng of each luciferase reporter construct (the wt or mt 3′-UTR of ARID2 mRNA) and miR-155 expression vector, miR-155 inhibitor, control vector or negative control (50 nM) using FuGENE (Promega). After 48 h, the cells were harvested and luciferase activity was measured using the dual-luciferase reporter assay system (Promega). Firefly luciferase activity was normalized to the Renilla luciferase activity. Results were obtained from three independent experiments performed in triplicate.

In vivo experiments

Four-to-six-week-old female BALB/c nude mice (Centre of Laboratory Animals, The Medical College of Xi'an Jiaotong University, Xi'an, China) were used to establish the nude mouse xenograft model. SMMC-7721 (5×106) cells that were transfected with anti-miR-155 or anti-miR-NC vectors were mixed in 150 μl of Matrigel and were inoculated subcutaneously into the flank of nude mice. The tumor volume for each mouse was determined by measuring two of its dimensions and then calculated as tumor volume = length × width × width/2. After 3 weeks, the mice were sacrificed by cervical dislocation under anesthesia with ether and the xenograft tumor tissue was explanted for examination. Animal protocols were approved by the Institutional Animal Care and Use Committee of Xi'an Jiaotong University.

Statistical analysis

Data are presented as the mean ± SD from at least three independent replicates. SPSS software, 16.0 (SPSS, Inc, Chicago, IL, USA) was used to conduct the analysis, and a two-tailed Student's t-test was employed to analyze the differences between two groups. Pearson's correlation analysis was used to analyze the correlation between two indices. Survival curves were plotted by the Kaplan-Meier method and compared by the log-rank test. Differences were considered statistically significant at P<0.05.

Results

miR-155 is upregulated in HCC tissues and cells

To evaluate the potential role of miR-155 in HCC, we first quantified miR-155 in 124 pairs of HCC tissues and matched adjacent non-tumor tissues using qRT-PCR methods. As shown in Fig. 1A, miR-155 was significantly increased in the HCC tissues compared with adjacent non-tumor tissues. Furthermore, we determined the expression level of miR-155 in HCC cell lines and the normal hepatocyte cell line LO2. Similarly, miR-155 was significantly upregulated in all HCC cell lines compared with LO2 cells (P<0.05, Fig. 1B). These results suggest that miR-155 expression is upregulated in HCC and may contribute to the development of HCC.

Figure 1 miR-155 is highly expressed in HCC tissues and cell lines. (A) Relative miR-155 expression levels in HCC tissues and matched adjacent non-tumor tissues were determined by qRT-PCR (n=124). (B) The expression of miR-155 in HCC cell lines was significantly increased compared to that in the LO2 cells. U6 snRNA was used as internal control. *P<0.05, **P<0.01.

Clinical significance of elevated miR-155 expression in HCC specimens

To investigate the clinical significance of miR-155 in HCC, the patients were classified into high and low miR-155 expression subgroups with the median level of miR-155 as the cut-off. As shown in Table I, higher levels of miR-155 were significantly correlated with a large tumor size (≥5 cm; P=0.001), high histological grade (Edmondson-Steiner grade III + IV; P=0.021) and advanced tumor stage (TNM stage III + IV; P=0.020) (Table I). To further evaluate the significant contribution of miR-155 expression in the prognosis of patients with HCC, we constructed Kaplan-Meier survival curves using the overall 5-year patient survival data to analyze cases with high and low miR-155 expression. As shown in Fig. 2, patients with high miR-155 expression exhibited worse overall survival (P=0.0004) and disease-free survival (P=0.0006). These data indicate that miR-155 could serve as a valuable indicator for predicting the prognosis of HCC.

Figure 2 The prognostic value of miR-155 for HCC patients assessed by Kaplan-Meier analysis. HCC patients with high expression of miR-155 had worse (A) overall survival (OS) and (B) disease-free survival (DFS). **P<0.01.

Table I Clinical correlation of miR-155 expression in HCC (n=124).

Table I

Clinical correlation of miR-155 expression in HCC (n=124).

		Expression level
Clinical parameters	Cases (n)	miR-155high (n=68)	miR-155low (n=56)	P-value (p<0.05)a
Age
<50 years	39	20	19	0.698
≥50 years	85	48	37
Gender
Male	92	50	42	0.852
Female	32	18	14
Tumor size (cm)				0.001a
<5 cm	88	40	48
≥5 cm	36	28	8
Tumor number				0.947
Solitary	106	58	48
Multiple	18	10	8
Edmondson
I+II	77	36	41	0.021a
III+IV	47	32	15
TNM stage				0.020a
I+II	102	51	51
III+IV	22	17	5
Capsular infiltration				0.826
Present	81	45	36
Absent	43	23	20
Venous infiltration				0.668
Present	15	9	6
Absent	109	59	50
AFP				0.569
<400 ng/ml	41	21	20
≥400 ng/ml	83	47	36
HBsAg				0.964
Positive	115	63	52
Negative	9	5	4

miR-155 promotes cell cycle progression, cell proliferation and inhibits apoptosis in HCC cells

To investigate the biological function of miR-155 in the development and progression of HCC, we transduced a miR-155 expression vector or a miR-155 inhibitor (anti-miR-155) into Hep3B and SMMC-7721 cells, respectively. As measured by qRT-PCR, miR-155 expression vector significantly increased the level of miR-155 in Hep3B cells, while the anti-miR-155 vector significantly reduced the expression of miR-155 in SMMC-7721 cells (P<0.01, Fig. 3A). As determined by flow cytometric analysis, the upregulation of miR-155 promoted cell cycle transition from G1 to S phase (P<0.05, Fig. 3B) and apoptosis resistance (P<0.05, Fig. 3C) in Hep3B cells. Furthermore, the overexpression of miR-155 significantly increased cell proliferation examined with incorporation assay in Hep3B cells (P<0.05, Fig. 3D). By contrast, the downregulation of miR-155 resulted in G1 arrest, apoptosis promotion and proliferation reduction in SMMC-7721 cells (P<0.05, respectively, Fig. 3B–D). These results demonstrated that miR-155 regulates the cell cycle progression, apoptosis and proliferation of HCC cells.

Figure 3 miR-155 promotes HCC cell cycle transition, cell proliferation and apoptosis resistance. (A) Hep3B and SMMC-7721 cells that were transfected with corresponding miRNA vectors were subjected to qRT-PCR for miR-155. (B) As assessed by flow cytometry, overexpression of miR-155 promoted cell cycle transition from G1 to S-phase in Hep3B cells and knockdown of miR-155 induced G1 phase arrest in SMMC-7721 cells. (C) Quantification of the apoptotic cell population by flow cytometry. Overexpression of miR-155 inhibited apoptosis in Hep3B cells and knockdown of miR-155 increased the percentage of apoptotic SMMC-7721 cells compared with the control cells. (D) Cell proliferation as measured by BrdU incorporation assays was increased by overexpression of miR-155 in Hep3B cells and inhibited by knockdown of miR-155 in SMMC-7721 cells. Representative micrographs (left) and quantification (right) of BrdU incorporating-cells of indicated cells. Experiments were repeated at least 3 times with similar results, and error bars represent mean ± SD. *P<0.05, **P<0.01.

ARID2 is a direct target of miR-155 in HCC

To explore the mechanism of miR-155 regulation in HCC, we used publicly available databases TargetScan 6.2 and miRanda to search predicted genes. Among them, the binding sites for miR-155 on the 3′-UTR of ARID2 were conserved among species (Fig. 4A). To verify the regulation role of miR-155 on ARID2, qRT-PCR and western blotting were performed to detect the effect of miR-155 on ARID2 mRNA and protein levels. Ectopic expression of miR-155 markedly decreased, while inhibition of miR-155 increased the ARID2 mRNA (P<0.05, Fig. 4B) and protein (P<0.05, Fig. 4C). In addition, the over-expression of miR-155 prominently inhibited the luciferase activity of ARID2 containing a wild-type (wt) 3′-UTR but did not suppress the activity of ARID2 with a mutant (mt) 3′-UTR (P<0.01, Fig. 4D). Suppression of miR-155 by anti-miR-155 increased the luciferase activity of wt ARID2 3′-UTR (P<0.01, Fig. 4D). However, with the mt ARID2 3′-UTR constructs, there was no relative increase in activity. Moreover, the expression levels of ARID2 mRNA and protein in the high miR-155 expression tumors were significantly lower than those in the low miR-155 expression tumors (P<0.05, respectively, Fig. 4E and F). Notably, the expression level of miR-155 was inversely correlated with the level of ARID2 mRNA in HCC tissues (R2=0.8393, P<0.0001, Fig. 4G). On the basis of these data, we conclude that ARID2 is a direct target gene for miR-155 and that miR-155 downregulates ARID2 expression.

Figure 4 ARID2 is a direct target of miR-155 in HCC cells. (A) TargetScan demonstrated that 3′-UTR of ARID2 contained the highly conserved putative miR-155 binding sites. (B) qRT-PCR analysis of ARID2 mRNA expression in Hep3B cells with miR-155 or control (miR-control) transfection and SMMC-7721 cells with anti-miR-155 or anti-miR-NC (negative control) vector transfection. (C) Overexpression of miR-155 reduced the expression of ARID2 protein in Hep3B cells and knockdown of miR-155 increases the level of ARID2 protein in SMMC-7721 cells. (D) miR-155 significantly suppresses the luciferase activity that carried wild-type (wt) but not mutant (mt) 3′-UTR of ARID2. Anti-miR-155 led to a notable increase in the luciferase activity of wt 3′-UTR of ARID2. (E) The expression of ARID2 mRNA in miR-155 high-expressing tumors was significantly lower than that in miR-155 low-expressing tumors. (F) A significant inverse correlation between miR-155 and ARID2 protein expression was observed in HCC tissues. Representative immunohistochemical staining showed a weak staining of ARID2 in miR-155 high-expressing HCC tissue and strong staining of ARID2 in the miR-155 low-expressing tumor. (G) A statistically significant inverse correlation was shown between miR-155 and ARID2 mRNA levels in HCC specimens by Spearman's correlation analysis. Experiments were repeated at least 3 times with similar results. *P<0.05, **P<0.01.

Altering expression of ARID2 influences the effect of miR-155 on HCC cells

To confirm that ARID2 is a functional target of miR-155, we restored ARID2 expression in Hep3B-miR-155 cells by transfecting ARID2 expression plasmid (P<0.05, Fig. 5A). Functionally, restoration of ARID2 expression in Hep3B-miR-155 cells partially abrogated the effect of exogenous miR-155, resulting in significant increase of apoptosis (P<0.01, Fig. 5C) and obvious decrease of cell cycle progression and cell proliferation (P<0.05, respectively, Fig. 5B and D). Similarly, silencing of ARID2 in SMMC-7721-anti-miR-155 cells partially abolished the effect of anti-miR-155 on cell cycle, apoptosis and proliferation (P<0.05, respectively, Fig. 5). These results demonstrate that ARID2 is a downstream mediator for the function of miR-155 in HCC.

Figure 5 Alterations of ARID2 partially abolish miR-155-mediated HCC cell cycle progression, proliferation and apoptosis. (A) miR-155-overexpressing Hep3B that were transfected with EV or ARID2 expression plasmid and miR-155-suppressive SMMC-7721 cells that were transfected with control siRNA or ARID2 siRNA were subjected to western blot analysis for ARID2. (B) G1 phase arrest was induced after ARID2 overexpression in miR-155-overexpressing Hep3B cells. The cell cycle transition from G1 to S-phase was increased by ARID2 knockdown in miR-155-suppressive SMMC-7721 cells. The correlations between miR-155 effects and ARID2 overexpression or knockdown are shown in (C) apoptosis and (D) cell proliferation. ARID2 overexpression induced effects that were opposite to those stimulated by miR-155 overexpression in Hep3B cells. ARID2 knockdown abrogated the effects of miR-155 knockdown on SMMC-7721 cells. n, three independent experiments. *P<0.05, **P<0.01.

Akt phosphorylation is essential for the biological function of miR-155 in HCC

Previous studies demonstrated that activation of Akt signaling played an important role in HCC cell cycle progression, apoptosis and proliferation (20–22), so we further investigated the underlying molecular mechanisms of the miR-155-mediated promotion of HCC biological effects. As shown in Fig. 6A, ectopic expression of miR-155 significantly increased, while miR-155 inhibition decreased, the Akt phosphorylation in HCC cells (P<0.05). Consistently, the expression of Cyclin D1 and p27, which are the downstream effectors of Akt signaling and the key regulators of cell cycle progression and proliferation in HCC, were also altered in the up- or down-expression of miR-155 HCC cells (P<0.05). Furthermore, to confirm that Akt phosphorylation contributed to the biological function of miR-155-mediated in HCC cells, we used Akt inhibitor or pmyr-Akt (dominant-active Akt) plasmid to affect Akt activation. Inactivation of Akt phosphorylation by Akt inhibitor significantly decreased cell cycle progression (P<0.05, Fig. 6B) and proliferation (P<0.05, Fig. 6D) and induced apoptosis (P<0.05, Fig. 6C) in Hep3B-miR-155 cells. In addition, Akt overexpression of phosphorylation increased cell cycle progression, cell proliferation and inhibited apoptosis (P<0.05, respectively, Fig. 6B–D) in SMMC-7721-anti-miR-155 cells. Accordingly, the expression of Cyclin D1 and p27 was also significantly altered (P<0.05, Fig. 6E). Taken together, our results demonstrate that Akt phosphorylation exerts an important role in miR-155-mediated HCC cell cycle progression, apoptosis and proliferation.

Figure 6 Activated Akt phosphorylation signaling is essential for miR-155-promoted HCC cell cycle progression, proliferation and miR-155-inhibited apoptosis. (A) Western blot analysis of p-Akt, total Akt, Cyclin D1 and p27 protein levels in indicated cells. Quantification of cell cycle (B), apoptosis (C) and cell proliferation (D) in indicated HCC cells treated with Akt inhibitor (0.5 μM) or transfected with dominant-active Akt plasmid. (E) The protein expression level of Cyclin D1 and p27 by western blot analysis in indicated HCC cells treated with Akt inhibitor (0.5 μM) or transfected with dominant-active Akt plasmid. Experiments were repeated at least 3 times with similar results, and error bars represent mean ± SD. *P<0.05.

miR-155 promotes HCC cell cycle progression, proliferation and inhibits apoptosis in vivo

To further confirm our results in vivo, SMMC-7721 cells were transfected with anti-miR-155 or anti-miR-NC vector and implanted subcutaneously into nude mice (Fig. 7A). Notably, the tumor growth curve revealed that knockdown of miR-155 significantly retarded the tumor growth of human HCC in the subcutaneous nude mouse model (P<0.001, Fig. 7B). As shown in Fig. 7C, in the miR-155 knockdown group, the tumor weight was smaller than that in the control group. Furthermore, the downregulation of miR-155 in the tumor formation in the subcutaneous model (P<0.05, Fig. 7D), inhibited the activation of Akt signaling (P<0.05, Fig. 7E). Taken together, these results demonstrated that miR-155 regulates the cell cycle progression, apoptosis and cell proliferation of HCC cells and contributed to the development and progression of HCC.

Figure 7 miR-155 promotes HCC growth by activating Akt signaling in vivo. (A) Representative images of HCC xenografts from both SMMC-7721 anti-miR-NC (upper panel) and SMMC-7721-anti-miR-155 cells (lower panel). Tumor growth curve (B) and weight (C) revealed that miR-155 knockdown significantly inhibited tumor growth in vivo. (D) Expression of miR-155 in miR-155 inhibitor-treated tumors from the subcutaneous model. (E) Expression of p-Akt, Akt, Cyclin D1, p27 were assessed in the subcutaneous model by western blotting. *P<0.05, **P<0.01.

Discussion

miRNAs are known to be regulators of many genes at the post-transcript level, and their aberrant expression is related to cancer initiation, development and prognosis (23). However, the molecular mechanisms by which miRNAs modulate the biological function of cancer cells are still largely unknown. In previous studies, miR-155 controls affinity-based selection by protecting c-MYC+ B cells from apoptosis (24). Lerner et al indicated that miR-155 was upregulated in blood, tissue and cell lines of head and neck squamous cell carcinoma and could serve as an independent prognosis predictor for patients and promoted the cell proliferation and migration (25). Moreover, Hou et al found that miR-155 promoted non-small cell lung carcinoma proliferation through inhibition of FoxO1 and the subsequent increase of ROS generation (26).

In this study, we initially investigated the expression of miR-155 in 124 paired samples of HCC and non-tumor tissues. Our data showed that the expression of miR-155 was elevated in HCC tissues. Furthermore, miR-155 was upregulated in HCC cell lines as compared with a normal hepatic cell line. These results indicate that miR-155 may be an oncogene and may play a critical role in hepatocarcinogenesis. Importantly, its upregulation significantly correlated with the poorer prognosis of patients with HCC. In addition, elevated miR-155 expression was significantly correlated with malignant clinicopathological featurs of HCC, including large tumor size, high histological grade and TNM stage. miR-155 has been found to promote proliferation of lung cancer by repressing FoxO1. We found that the downregulation of miR-155 inhibited HCC cell proliferation and induced G1 phase arrest and apoptosis in vitro. By contrast, the overexpression of miR-155 promoted proliferation and cell cycle transition to S phase and inhibited apoptosis. These results suggested that miR-155 is a novel tumor-promoting miRNA that plays a critical role in the regulation of tumor growth in HCC.

To further understand the underlying mechanisms by which miR-155 exerts its biological effects on HCC cells, it is necessary to identify its downstream functional targets. ARID2, a new tumor suppressor gene in HCC, was initially identified in the Polybromo-associated BRG1-associated factor (PBAF) complex (27), an SWI/SNF chromatin remodeling complex involved in ligand-dependent transcriptional activation by nuclear receptors (28). Downregulated expression of ARID2 has been observed in liver cancer cells (29). We identified ARID2 as a novel direct target of miR-155. Firstly, miR-155 negatively regulated ARID2 mRNA and protein in HCC cells. Secondly, overexpression of miR-155 decreased, while downregulation of miR-155 increased, the luciferase reporter activity of ARID2 wt 3′-UTR, but not mt 3′-UTR. Thirdly, miR-155 was inversely correlated with the levels of both ARID2 mRNA and protein in HCC tissues. Finally, the effects of miR-155 alteration on cell cycle progression, apoptosis and proliferation were also abolished by ARID2 modulation. Collectively, our results support that miR-155 exerts its biological function on HCC through targeting ARID2.

It has been well-established that Akt phosphorylation could promote cell cycle progression and proliferation through upregulation of Cyclin D1 and downregulation of p27 (22). As miR-155 plays a critical role in cell fate, a better understanding of its regulatory axis might provide new opportunities for developing more effective therapeutic approaches to treat cancers. In addition, we discovered that miR-155 activated Akt phosphorylation through targeting ARID2. Consistently, we performed loss-experiment by Akt inhibitor, gain-experiment by dominant-active Akt plasmid to confirm that Akt phosphorylation plays an important role in the miR-155-mediated biological function. In addition, we discovered miR-155 activated Akt signaling through targeting ARID2 in vivo, suggesting miR-155 may represent as a potential therapeutic target for HCC treatment.

In conclusion, we find that miR-155 is upregulated in HCC tissues and cells, and its elevated expression is associated with poor prognostic features. In vitro and in vivo studies indicate that miR-155 promotes tumor growth by promoting HCC cell cycle progression, cell proliferation and inhibiting apoptosis. Mechanistically, we suggest that miR-155 exerts its biological function through Akt phosphorylation by targeting ARID2. Therefore, miR-155 has the potential to be a valuable diagnostic and prognostic biomarker for HCC.

Acknowledgements

This study was supported by the Science and Technology Research and Development Program of Shaanxi Province [2013k-12].

References